These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15252156)

  • 21. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis].
    Kumagai H; Sakata K; Matsuura T; Imai M; Onami T; Iigaya K; Saruta T
    Nihon Rinsho; 2002 Oct; 60(10):2005-13. PubMed ID: 12397699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O; Kusano E; Tanba K; Yanagiba S; Amemiya M; Ando Y; Honma S; Muto S; Asano Y
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J
    J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
    Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
    Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K; Lill M; Boor P; Heidland A; Amann K
    Am J Nephrol; 2009; 29(3):164-70. PubMed ID: 18753741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure].
    Gutiérrez E; González E; Morales E; Herrero JC; Manzanera MJ; García JA; Domínguez-Gil B; Hernández E; Praga M
    Nefrologia; 2004; 24(6):546-52. PubMed ID: 15683026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency.
    Weinbergová O; Metelka R; Vymetal J; Konecný K; Kosatíková Z
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2004 Jul; 148(1):69-73. PubMed ID: 15523550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin blockade as sole treatment for proteinuric kidney disease in children.
    Chandar J; Abitbol C; Montané B; Zilleruelo G
    Nephrol Dial Transplant; 2007 May; 22(5):1332-7. PubMed ID: 17299000
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
    Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
    Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
    Berger ED; Bader BD; Ebert C; Risler T; Erley CM
    J Hypertens; 2002 Apr; 20(4):739-43. PubMed ID: 11910311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective? ].
    Morales E; Huerta A; Gutiérrez E; Gutiérrez Solís E; Segura J; Praga M
    Nefrologia; 2009; 29(5):421-9. PubMed ID: 19820754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.